Wechselwirkungen · Hepcludex
HEPCLUDEX 2 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-142408 · Präparat HOS-098824
No CYP inhibition by bulevirtide was observed in vitro at clinically relevant concentrations. However, in a clinical study, an approximately 40% increase in geometric mean of partial AUC2-4h values of co-administered midazolam (CYP3A4 substrate) was observed in combination of high dose bulevirtide (10 mg) and tenofovir (245 mg), whereas no significant influence on midazolam AUC2-4h was detected for tenofovir alone. As a precautionary measure, close clinical monitoring is warranted for co-administered narrow-therapeutic-index drugs which are sensitive CYP3A4 substrates (e.g. cyclosporine, carbamazepine, simvastatin, sirolimus, and tacrolimus).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) carbamazepine (HOS-085618) simvastatin (HOS-086158) tacrolimus (HOS-085202) sirolimus (HOS-085172) cyclosporine (HOS-084512) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-31T10:15:00Z · SHA-256 56ea5f48399773f9051c5a5cc519d740db7ee3cdff519ad40c96b180c39a4a0f · Passage 8920a90593f9ec713fdabc27d9117294cea77d961240563dae041ca129d15af9 · Zeichen 1537–2187 im Abschnitt